Last reviewed · How we verify
GSK961081 800 microgram dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK961081 800 microgram dose (GSK961081 800 microgram dose) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK961081 800 microgram dose TARGET | GSK961081 800 microgram dose | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK961081 800 microgram dose CI watch — RSS
- GSK961081 800 microgram dose CI watch — Atom
- GSK961081 800 microgram dose CI watch — JSON
- GSK961081 800 microgram dose alone — RSS
Cite this brief
Drug Landscape (2026). GSK961081 800 microgram dose — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk961081-800-microgram-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab